Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.05 per share when it actually produced a loss of $0.10, delivering a surprise of -100%.Over the last four ...